Key result
Baseline SAQ scores and treatment-related improvements vary across angina trials.
Answers are grounded in this paper and cite their sources.
This review of multiple trials highlights the relationship between baseline Seattle Angina Questionnaire scores, coronary physiology (such as FFR), and the magnitude of symptom improvement following angina treatment.
Left panel. Mechanisms of angina and modifiers of treatment effect. Upper right panel. Baseline SAQ vs SAQ change across trials. We reported SAQ at 6-months as time point for all trials, except for ORBITA (6-weeks) and ORBITA-2 (12-weeks). We reported SAQ-SS when available (ISCHEMIA, CorMicA, ILIAS-ANOCA, CorCMR), otherwise we calculated SAQ-SS by averaging the individual domain scores for angina frequency, physical limitation, and quality of life (COURAGE and ORBITA-2) or angina frequency, physical limitation, and angina stability (ORBITA). Lower right panel. Baseline SAQ vs SAQ change across trials according to the implementation of physiology. ORBITA-2 Lower FFR quartile: FFR < 0.46; upper FFR quartile: FFR > 0.73. CFT, coronary function testing; CMD, coronary microvascular dysfunction; FFR, fractional-flow reserve; SAQ, Seattle Angina Questionnaire.
No takes yet. Share an insight, caveat, or question.
Montone et al. (2026) conducted a review in angina pectoris. Treatment of angina pectoris was evaluated on SAQ change. Baseline Seattle Angina Questionnaire (SAQ) scores and SAQ changes were evaluated across multiple trials for the treatment of angina pectoris.
Synapse has enriched 10 related papers. Consider them for comparative context: